Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Nicoleta Elena Calomfirescu
Dr. Marius Vicea Calomfirescu
The Reynolds Risk Score and the measure of adiponectin are new and useful tools to evaluate cardiovascular risk in women more accurately.
Cardiovascular disease in women, their specific symptoms in presenting myocardial infarction and the Women at Heart initiative have been brought to you in a previous volume of the e-Journal, in 2006. Since, the ESC/EACPR 2007 guidelines have exposed the misleading or incomplete issues regarding this category of risk - being female- in a dedicated a section (1) and among issues raised were:
Taken together, these findings indicate that the Heart Score and/or other classical charts are not fully suited to quantify risk in women. New tools, whether methods or charts, are needed for better evaluation of women's specific cardiovascular risk, especially at its early stages.
Epicardial adipose tissue may be an important regulator of patho-physiological processes contributing to coronary artery diseases (CAD), through local production of various cytokines and adipocytokines. (7,8) Body mass index, waist circumference and waist to hip ratio can be used to evaluate obesity. However, BMI is a poor measure of body fat in the over age 65 population mainly, due to sarcopenic obesity, that is due to age-related reduction in skeletal muscle mass. Waist circumference and waist to hip ratio are the preferred methods in this population. Furthermore, the values of the parameters listed above have cut-off values that differ by race, sex, and other factors. It is believed that adipose tissue secretes adipocytokines which influence cardiovascular risk, of which adiponectin, first discovered over twenty years ago, is a member. Adiponectin is secreted by white adipose tissue (as opposed to brown) and levels are low in obese people. (7,8) Indeed, levels of the hormone are inversely correlated with body fat percentage in adults. Levels of adiponectin are also influenced by smoking, age, and sex. There are added correlations with risk factors such as total cholesterol, HDL cholesterol as well as inflammatory markers, hs protein C and interleukins (9). Adiponectin is likely to play an important role in the interplay between metabolic changes and cardiovascular risk, however the central question is whether levels - high or low - indicate protection against atherosclerosis and cardiovascular disease. In women without cardiovascular disease, high plasma adiponectin levels are correlated with low cardiovascular risk. In women with cardiovascular diseases however, high plasma levels reflect a high risk. (10,11)
We attempted to establish whether there is a link between adiponectin plasma levels and the Reynolds Risk Score in women with metabolic syndrome but without any major cardiovascular event (12). Findings showed that women with metabolic syndrome have a lower level of adiponectin compared to women without syndrome thus plasma adiponectin alone may be of little value in the diagnosis of metabolic syndrome. Unfortunately, no correlation could be established between plasma adiponectin levels and RRS. These findings are paradoxical. However, they might be explained by the fact that adiponectin homeostasis is differently regulated during chronic inflammatory states, such as established CVD, which increase adiponectin concentrations independently of adipose tissue regulatory mechanisms. Patients with rheumatoid arthritis for instance, another chronic inflammatory condition, have higher adiponectin levels and increased inflammatory status compared with healthy controls. Further studies are needed to confirm the value of RRS in women and to elucidate the role of adiponectin in these processes of atherosclerosis. Nevertheless, a very recent case-cohort sample of the multi-ethnic Women's Health Initiative Observational Cohort with 1722 cases of major CVD and a random subcohort of 1994 women without prior CVD demonstrated that the Reynolds Risk Score is better calibrated than the Framingham-based models to predict global cardiovascular risk (13). Corroborating all data, a theoretical mechanism of adiponectin and cardiovascular risk linked RRS was part of Author's PhD thesis. (Fig. 1)
1.European Guidelines cardiovascular disease prevention in clinical practice: Executive Summary, EHJ, (2007),28:2375-2414. 2.Improving Cardiovascular Risk Prediction for Women, Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. Ridker PM, Burning JE, Rifai N, Cook NR. JAMA 2007; 297:611-9. 3.Reynolds Risk Score Calculating Heart &Stroke Risk for Women retrieved from: http://www.reynoldsriskscore.org/ on 23-th of March 2012 4.C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men: Results From the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Koenig W, Sund M., Frohlich M, Fischer H.G, Lowel H, Doring A. & all; Circulation: Volume 99(2) 19 January 1999pp 237-242 5.C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Folsom, A. R. A, Nena D, Catellier M, Juneja D, Harinder S. Wu, Kenneth K. ; American Heart Journal: Volume 144(2) August 2002 pp 233-238 6.The Clinical Impact of Reynolds Risk Score in United States Women. Tattersall M.C, Karmali K.N, Keevil G.C ; Circulation. 2008;118:S_1121 7.Adipose tissue as an endocrine organ: implications of its distribution on free fatty acid metabolism. Jensen M.D.; EHJ Supplements (2006), B13-B19 8.A novel serum protein similar to C1q produced exclusively in adipocytes. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF; J Biol Chem 270:26746–26749, 1995 9.Relationship Between Adiponectin and Glycemic Control, Blood Lipids, and Inflammatory Markers in Men With Type 2 Diabetes. Schulze M, Eric B. Rimm, Iris Shai, RD, Nader Rifai, Frank B. Hu; Diabetes Care 27:1680-1687, 2004. 10.Prognostic value of adiponectin for cardiovascular disease and mortality. Dekker J.M, Funahashi T, Nijpels G, Pilz S, Stehouver CDE, Snijder MB, Bouter LM, Matsuzawa Y, Shimomura I, Heine RJ.; J Clin Endocrinol Metab 2008, Jan 22 11.Adiponectin and protection against type 2 diabetes mellitus. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF ; Lancet 361: 226 –228,2003 12.Circulating Adiponectin: Associations with Risk Factors and the Reynolds Risk Score in Women without Prior Major Cardiovascular Events. Calomfirescu N, Popa C, Jurcut R, Serban M, Ginghina C.; Cardiology, 115(1), pp. 64-70, 2010. 13.Comparison of the Framingham and Reynolds Risk Scores for Global Cardiovascular Risk Prediction in the Multiethnic Women's Health Initiative. Cook NR, Paynter NP, Eaton CB, Manson JE, Martin LW, Robinson JG, Rossouw JE, Wassertheil-Smoller S, Ridker PM. ; Circulation. 2012 Mar 7. [Epub ahead of print]
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
Nicoleta Elena CALOMFIRESCU, MD, PhD, MBA, Cardiology Senior Consultant Marius Vicea CALOMFIRESCU - MD, PhD, Ob-Gyn Senior Consultant, Maternal-Fetal Medicine Specialist, Fetal Medicine Foundation Certified Authors' disclosures: None declared.